Press Releases

16 Nov 2018 Podcast: Listen to Shane Schaffer talk with Dan Levine of the Bio Report

Shane Schaffer sits down with Dan Levine of the Bio Report to discuss ADHD, Cingulate’s Precision Timed Release(TM) drug delivery technology, and the clinical path forward.

07 Sep 2018 BDD Pharma and Cingulate Therapeutics Complete License Agreement for OralogiK™ Enabled Triple Pulse Products

GLASGOW, Scotland and Kansas City, KS – (September 7, 2018) – BDD Pharma, a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations, and Cingulate Therapeutics, a clinical stage biopharmaceutical company, today announced that the

11 Jul 2018 Cingulate Therapeutics Announces $7.5M Equity Investment from Werth Family Investment Associates

Industry veteran Peter J. Werth to join Cingulate Therapeutics Board of Directors Kansas City, KS – (July 11, 2018) – Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery

31 May 2018 Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments

Kansas City, KS – (May 31, 2018) – Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the appointment of Jeff Conroy and Jeff

02 Apr 2018 Cingulate Therapeutics Appoints Laurie Myers, PhD, MBA as Chief Operating Officer

Kansas City, KS – (April 2, 2018) – Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the appointment of Laurie A. Myers, Ph.D.

15 Jan 2018 Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting

Kansas City, KS – (January 15, 2018) – Cingulate Therapeutics LLC a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the presentation of a poster titled,

09 Jan 2018 Cingulate Therapeutics Appoints Experienced Lead Investigator Matthew Brams, MD as Chief Medical Officer

Kansas City, KS – (January 9, 2018) – Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the appointment of Matthew Brams, MD to the

04 Jan 2018 Cingulate Therapeutics to Present New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting

Kansas City, KS – (January 4, 2018) – Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the acceptance of data from its proof of